Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SAGE 
Sage Therapeutic (SAGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/31/2025: SAGE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.58
1 Year Target Price $8.58
| 0 | Strong Buy |
| 3 | Buy |
| 15 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.04% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 544.94M USD | Price to earnings Ratio - | 1Y Target Price 8.58 |
Price to earnings Ratio - | 1Y Target Price 8.58 | ||
Volume (30-day avg) 19 | Beta 0.3 | 52 Weeks Range 4.62 - 9.36 | Updated Date 08/15/2025 |
52 Weeks Range 4.62 - 9.36 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate -0.945 | Actual -0.7967 |
Profitability
Profit Margin - | Operating Margin (TTM) -171.19% |
Management Effectiveness
Return on Assets (TTM) -33.78% | Return on Equity (TTM) -60.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 190791239 | Price to Sales(TTM) 7.74 |
Enterprise Value 190791239 | Price to Sales(TTM) 7.74 | ||
Enterprise Value to Revenue 2.71 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 62781400 | Shares Floating 51314943 |
Shares Outstanding 62781400 | Shares Floating 51314943 | ||
Percent Insiders 10.36 | Percent Institutions 83.59 |
Upturn AI SWOT
Sage Therapeutic
Company Overview
History and Background
Sage Therapeutics was founded in 2010 and is a biopharmaceutical company committed to developing and commercializing novel medicines to treat brain health disorders. They focus on developing treatments for conditions like postpartum depression (PPD), major depressive disorder (MDD), and other neurological disorders. The company has evolved from a research-focused organization to a commercial-stage company with approved products.
Core Business Areas
- Depression and Mood Disorders: Development and commercialization of treatments for postpartum depression (PPD), major depressive disorder (MDD), and other mood disorders.
- Neurology: Research and development of therapies for neurological disorders.
Leadership and Structure
The leadership team includes Barry Greene (Chief Executive Officer). The organizational structure typically includes research & development, commercial, and administrative functions. Specific details of the internal organizational structure are generally confidential.
Top Products and Market Share
Key Offerings
- Zulresso (brexanolone): Zulresso is an IV treatment approved for postpartum depression (PPD). Market share information is difficult to obtain precisely. The main competitor is oral medication developed by Biogen and Sage Therapeutics, Zurzuvae. Zulresso revenue for 2023 was $16.4 million.
- Zurzuvae (zuranolone): Zurzuvae is an oral medication approved for postpartum depression (PPD). It is developed in collaboration with Biogen. Market share is still evolving. The main competitor is Zulresso. Revenue from initial sales in Q4 2023 was $1.6 million and $0.3 million were associated with revenue deductions
Market Dynamics
Industry Overview
The brain health market is growing, with increasing awareness and demand for treatments for mental health conditions. It is characterized by high unmet needs, complex regulatory pathways, and significant research and development investment.
Positioning
Sage Therapeutics is positioned as an innovator in brain health, particularly in depression. Its competitive advantages include its proprietary pipeline and expertise in GABA modulation.
Total Addressable Market (TAM)
The global market for depression treatments is estimated to be in the billions of dollars. Sage Therapeutics is positioned to capture a significant portion of this market with its innovative therapies. Estimates suggest a multi-billion dollar market opportunity for novel depression treatments.
Upturn SWOT Analysis
Strengths
- Innovative pipeline
- Expertise in GABA modulation
- Approved products
- Strategic partnerships (e.g., with Biogen)
- Strong focus on unmet needs in brain health
Weaknesses
- Reliance on a limited number of products
- High R&D costs
- Commercialization challenges
- Dependence on collaboration partners
- Limited revenue base as of 2023
Opportunities
- Expansion into new indications
- Development of new therapies
- Partnerships and acquisitions
- Increasing awareness of mental health
- Regulatory support for innovative treatments
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Pricing pressures
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- VRAY
- ALKS
Competitive Landscape
Sage Therapeutics' advantage lies in its focused approach to brain health and innovative GABA modulation technology. Disadvantages include its smaller size and limited commercial infrastructure compared to larger pharmaceutical companies. However, LLY and ALKS are bigger established Pharma companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by significant R&D investment and regulatory approvals, with fluctuating stock prices reflecting clinical trial results and market sentiment.
Future Projections: Future growth depends on successful commercialization of existing products and pipeline advancement. Analyst estimates vary, but generally project revenue growth with potential profitability in the long term.
Recent Initiatives: Recent initiatives include expanding the label for Zurzuvae and advancing new drug candidates in its pipeline.
Summary
Sage Therapeutics is a developing biopharmaceutical company focused on brain health with approved products, including Zulresso and Zurzuvae. Its reliance on a few products and continuous need of R&D pose significant risks. They have strategic partnerships to offset these risks. The company's long-term success depends on the successful commercialization of its products, development of new therapies, and effective management of competition and regulatory challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sage Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are approximate and based on available data. Financial data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sage Therapeutic
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2014-07-18 | President, CEO & Director Mr. Barry E. Greene | ||
Sector Healthcare | Industry Biotechnology | Full time employees 353 | Website https://www.sagerx.com |
Full time employees 353 | Website https://www.sagerx.com | ||
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.